# Debate Matchup Judgment Report

- template_id: `judge_judge_blend_20260724a__debate_placement_active_20260320f`
- side_swap_group_id: `prop_0582__deepseek-v4-pro__glm-5-2__tpl_placement_active_20260320f`
- topic_id: `prop_0582`
- matchup: **DeepSeek V4 Pro** vs **GLM-5.2 (max)**
- overall judged result (normalized): **DeepSeek V4 Pro**
- overall judged result (raw): **DeepSeek V4 Pro**
- mean entertainment: `6.83 / 10`
- mean signed normalized margin for `DeepSeek V4 Pro`: `+1.06`
- judgment rows: `6`
- swap_complete: `1`
- rating_eligible: `1`

**Motion:** Over the next five years, allowing Medicare to cover GLP-1–class anti-obesity drugs broadly will reduce total US healthcare spending after accounting for drug costs.

## Source Links

- [Debate A transcript](../../../transcripts/prop_0582__deepseek-v4-pro__glm-5-2__s0__tpl_placement_active_20260320f.md): PRO = **DeepSeek V4 Pro**, CON = **GLM-5.2 (max)**
- [Debate B transcript](../../../transcripts/prop_0582__glm-5-2__deepseek-v4-pro__s1__tpl_placement_active_20260320f.md): PRO = **GLM-5.2 (max)**, CON = **DeepSeek V4 Pro**
- [Rolling judgment CSV](../../../judgments/judge_results__judge_blend_20260724a.csv)
  Search for `side_swap_group_id=prop_0582__deepseek-v4-pro__glm-5-2__tpl_placement_active_20260320f` or topic `prop_0582`.

## Debate A

- debate_id: `prop_0582__deepseek-v4-pro__glm-5-2__s0__tpl_placement_active_20260320f`
- transcript: [read transcript](../../../transcripts/prop_0582__deepseek-v4-pro__glm-5-2__s0__tpl_placement_active_20260320f.md)
- roles: PRO = **DeepSeek V4 Pro**, CON = **GLM-5.2 (max)**
- judged result: Split `2-1` for **DeepSeek V4 Pro**.
- entertainment scores: `7`, `5`, `8`
- mean signed raw margin (PRO+): `+0.33`

| Judge | Winner | Signed Margin (PRO+) | Normalized | Entertainment |
| --- | --- | ---: | ---: | ---: |
| GPT-5.5 (high) | GLM-5.2 (max) | -2.0 | -2.14 | 7.0 |
| Grok 4.3 | DeepSeek V4 Pro | +1.5 | +1.80 | 5.0 |
| Qwen 3.6 Max Preview | DeepSeek V4 Pro | +1.5 | +1.50 | 8.0 |

### Judge Notes

- **GPT-5.5 (high)**: B won by making the decisive arithmetic clearer: broad coverage creates continuous drug costs for millions, while A relied on cherry-picked avoided catastrophes without proving that the average persister generates enough expected savings to offset persisters and discontinuers...
  Most decisive rebuttal noted: B's strongest exchange was in Rebuttal 2 and closing: it reframed A's one avoided hospitalization examples as non-average, episodic savings, contrasting them with relentless monthly drug costs across all enrollees. That directly undercut A's central break-even story.
- **Grok 4.3**: Side A wins because it directly neutralized B's core routes (low persistence, additive costs, non-permanent savings) with plausible per-persister event-avoidance math and five-year window weighing that B only partially answered; B's closing shrinks savings to "modest" without...
  Most decisive rebuttal noted: A's Rebuttal 1 and 2 answers to B's adherence/window pressure, showing sunk dropout costs plus large event savings still net negative.
- **Qwen 3.6 Max Preview**: Side A wins by tightly leveraging the motion's explicit five-year constraint. When pressed on whether deferring a cost past year five counts as a saving inside the window, Side B conceded the point, effectively surrendering a major structural argument. Side A then successfully...
  Most decisive rebuttal noted: Side A's Rebuttal 2 directly neutralized the adherence pressure by reframing the math: because a single avoided catastrophic event covers years of drug costs for multiple patients, the program does not need high persistence to break even. This turned Side B's strongest attack...

## Debate B

- debate_id: `prop_0582__glm-5-2__deepseek-v4-pro__s1__tpl_placement_active_20260320f`
- transcript: [read transcript](../../../transcripts/prop_0582__glm-5-2__deepseek-v4-pro__s1__tpl_placement_active_20260320f.md)
- roles: PRO = **GLM-5.2 (max)**, CON = **DeepSeek V4 Pro**
- judged result: Unanimous `3-0` for **DeepSeek V4 Pro**.
- entertainment scores: `7`, `6`, `8`
- mean signed raw margin (PRO+): `-1.60`

| Judge | Winner | Signed Margin (PRO+) | Normalized | Entertainment |
| --- | --- | ---: | ---: | ---: |
| GPT-5.5 (high) | DeepSeek V4 Pro | -2.0 | -2.14 | 7.0 |
| Grok 4.3 | DeepSeek V4 Pro | -1.3 | -1.56 | 6.0 |
| Qwen 3.6 Max Preview | DeepSeek V4 Pro | -1.5 | -1.50 | 8.0 |

### Judge Notes

- **GPT-5.5 (high)**: Side B won by making the spending arithmetic clearer: immediate multi-year drug costs for millions of users swamp relatively slow and low-probability five-year medical offsets. Side A had plausible mechanisms and a good stacking argument, but relied heavily on speculative pric...
  Most decisive rebuttal noted: Side B's strongest exchange was answering the “parallel lotteries” argument: even stacked diabetes, cardiac, and orthopedic offsets have low event rates and do not approach cumulative pharmacy costs unless prices fall to roughly $2,000 per year, which Side B argued was unreali...
- **Grok 4.3**: B wins: stronger grounding on biologics pricing realities, broad-coverage mismatch, and realistic offset timing/magnitude after full exchange; multiple clips hurt B but did not erase substantive edge.
  Most decisive rebuttal noted: B's $2000 break-even concession plus A2 response on low-risk pool, which A never fully neutralized under the motion's broad requirement.
- **Qwen 3.6 Max Preview**: CON wins by effectively dismantling PRO's offset-stacking and price-drop assumptions. CON's distinction between small-molecule generic erosion and peptide/biologic pricing structures directly refuted PRO's core economic mechanism. CON also successfully leveraged the "broad cov...
  Most decisive rebuttal noted: CON's explanation that peptide manufacturing barriers and sterile fill-finish requirements prevent the 50-80% price crashes seen with statins, directly neutralizing PRO's primary path to a favorable five-year arithmetic.
